Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Accumulation of retained nonfunctional arteriovenous grafts correlates with severity of inflammation in asymptomatic ESRD patients.

Wasse H, Cardarelli F, De Staercke C, Hooper WC, Long Q.

Nephrol Dial Transplant. 2013 Apr;28(4):991-7. doi: 10.1093/ndt/gfs349. Epub 2012 Oct 22.

2.

Association of vascular access type with inflammatory marker levels in maintenance hemodialysis patients.

Dukkipati R, Molnar MZ, Park J, Jing J, Kovesdy CP, Kajani R, Kalantar-Zadeh K.

Semin Dial. 2014 Jul-Aug;27(4):415-23. doi: 10.1111/sdi.12146. Epub 2013 Oct 9.

PMID:
24118625
3.

Vascular access type, inflammatory markers, and mortality in incident hemodialysis patients: the Choices for Healthy Outcomes in Caring for End-Stage Renal Disease (CHOICE) Study.

Banerjee T, Kim SJ, Astor B, Shafi T, Coresh J, Powe NR.

Am J Kidney Dis. 2014 Dec;64(6):954-61. doi: 10.1053/j.ajkd.2014.07.010. Epub 2014 Sep 27.

4.

Association of advanced glycoxidation end products and inflammation markers with thrombosis of arteriovenous grafts in hemodialysis patients.

Cai W, Zhu L, Chen X, Uribarri J, Peppa M.

Am J Nephrol. 2006;26(2):181-5. Epub 2006 May 3.

PMID:
16675897
6.

Can serum NGAL levels be used as an inflammation marker on hemodialysis patients with permanent catheter?

Yigit IP, Celiker H, Dogukan A, Ilhan N, Gurel A, Ulu R, Aygen B.

Ren Fail. 2015 Feb;37(1):77-82. doi: 10.3109/0886022X.2014.975133. Epub 2014 Oct 27.

PMID:
25347233
7.
8.

C-reactive protein predicts vascular access thrombosis in hemodialysis patients.

Chou CY, Kuo HL, Yung YF, Liu YL, Huang CC.

Blood Purif. 2006;24(4):342-6. Epub 2006 Apr 5.

PMID:
16601326
9.

Inflammation from dialysis, can it be removed?

Achinger SG, Ayus JC.

Nephrol Dial Transplant. 2013 Apr;28(4):770-3. doi: 10.1093/ndt/gfs480. Epub 2012 Oct 28.

10.

Pentoxifylline decreases serum levels of tumor necrosis factor alpha, interleukin 6 and C-reactive protein in hemodialysis patients: results of a randomized double-blind, controlled clinical trial.

González-Espinoza L, Rojas-Campos E, Medina-Pérez M, Peña-Quintero P, Gómez-Navarro B, Cueto-Manzano AM.

Nephrol Dial Transplant. 2012 May;27(5):2023-8. doi: 10.1093/ndt/gfr579. Epub 2011 Oct 3.

11.

Role of the hemodialysis vascular access type in inflammation status and monocyte activation.

Colì L, Donati G, Cappuccilli ML, Cianciolo G, Comai G, Cuna V, Carretta E, La Manna G, Stefoni S.

Int J Artif Organs. 2011 Jun;34(6):481-8. doi: 10.5301/IJAO.2011.8466.

12.

The kind of vascular access influences the baseline inflammatory status and epoetin response in chronic hemodialysis patients.

Movilli E, Brunori G, Camerini C, Vizzardi V, Gaggia P, Cassamali S, Scolari F, Parrinello G, Cancarini GC.

Blood Purif. 2006;24(4):387-93. Epub 2006 Jun 1.

PMID:
16755161
13.

Comparison of markers of appetite and inflammation between hemodialysis patients with and without failed renal transplants.

Caliskan Y, Yelken B, Gorgulu N, Ozkok A, Yazici H, Telci A, Turkmen A, Yildiz A, Sever MS.

J Ren Nutr. 2012 Mar;22(2):258-67. doi: 10.1053/j.jrn.2011.07.005. Epub 2011 Nov 3.

PMID:
22056149
14.

Vascular access type and changes in inflammatory markers in incident dialysis patients: a pilot study.

Sachdeva M, Kovalchuk O, Bitzer M, Mokrzycki MH.

J Vasc Access. 2009 Jul-Sep;10(3):174-9.

PMID:
19670170
15.

Acute effect of hemodialysis on serum levels of the proinflammatory cytokines.

Tarakçioğlu M, Erbağci AB, Usalan C, Deveci R, Kocabaş R.

Mediators Inflamm. 2003 Feb;12(1):15-9.

16.

The impact of dialysis type on biomarkers for cardiovascular diseases.

Sahinarslan A, Güz G, Mutluay R, Okyay K, Demirtaş C, Paşaoğlu H, Yalçın R.

Turk Kardiyol Dern Ars. 2011 Sep;39(6):456-62. doi: 10.5543/tkda.2011.01289.

17.

Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.

Honda H, Qureshi AR, Heimbürger O, Barany P, Wang K, Pecoits-Filho R, Stenvinkel P, Lindholm B.

Am J Kidney Dis. 2006 Jan;47(1):139-48.

PMID:
16377395
18.

Is there association between acyl-ghrelin and inflammation in hemodialysis patients?

Barros Ade F, Moraes C, Pinto MB, Lobo JC, Mafra D.

J Bras Nefrol. 2013 Apr-Jun;35(2):120-6. doi: 10.5935/0101-2800.20130020. English, Portuguese.

19.

Comorbidity and acute clinical events as determinants of C-reactive protein variation in hemodialysis patients: implications for patient survival.

Snaedal S, Heimbürger O, Qureshi AR, Danielsson A, Wikström B, Fellström B, Fehrman-Ekholm I, Carrero JJ, Alvestrand A, Stenvinkel P, Bárány P.

Am J Kidney Dis. 2009 Jun;53(6):1024-33. doi: 10.1053/j.ajkd.2009.02.008. Epub 2009 Apr 25.

PMID:
19394732
20.

Inflammatory cytokines and malnutrition as related to risk for cardiovascular disease in hemodialysis patients.

Perunicic-Pekovic G, Pljesa S, Rasic-Milutinovic Z, Stankovic S, Ilic M, Maletic R.

Can J Physiol Pharmacol. 2008 Apr;86(4):205-9. doi: 10.1139/Y08-018.

PMID:
18418430
Items per page

Supplemental Content

Write to the Help Desk